2023 年第二次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 特别提示 1、为尊重中小投资者利益，提高中小投资者对公司股东大会审议的重大事 项参与度，本次股东大会审议的部分议案对中小投资者实行单独计票。中小投资 者是指除以下股东以外的其他股东：（1）上市公司的董事、监事、高级管理人员； （2）单独或者合计持有上市公司 5%以上股份的股东； 证券代码：002940 证券简称：昂利康 公告编号：2023-056 2、本次股东大会无否决或修改议案情况； 浙江昂利康制药股份有限公司 3、本次股东大会没有涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1、会议召开时间 现场会议召开时间：2023 年 8 月 17 日下午 14：30 网络投票时间：2023 年 8 月 17 日 其中：通过深圳证券交易所交易系统进行网络投票的具体时间为 2023 年 8 月 17 日上午 9：15 至 9：25，9：30 至 11：30 和下午 13：00 至 15：00； 通过深圳证券交易所互联网投票系统（http://wltp ...

证券代码：002940 证券简称：昂利康 公告编号：2023-055 浙江昂利康制药股份有限公司 关于子公司取得《兽药生产许可证》和 《兽药 GMP 证书》的公告 | 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 | | --- | | 误导性陈述或重大遗漏。 | 近日，浙江昂利康制药股份有限公司（以下简称"公司"）控股子公司浙江 昂利康动保科技有限公司（以下简称"动保科技"）收到浙江省农业农村厅签发 的《兽药生产许可证》、《兽药 GMP 证书》。现将有关情况公告如下： 1、《兽药生产许可证》 证号：兽药生产证字 11118 号 企业名称：浙江昂利康动保科技有限公司 生产范围：片剂、吸入麻醉剂 生产地址：浙江省绍兴市嵊州市剡湖街道嵊州大道北 1000 号-2 有效期：2023 年 8 月 7 日至 2028 年 8 月 6 日 2、《兽药 GMP 证书》 证书编号：（2023）兽药 GMP 证字 11008 号 企业名称：浙江昂利康动保科技有限公司 生产地址：浙江省绍兴市嵊州市剡湖街道嵊州大道北 1000 号-2 验收范围：片剂、吸入麻醉剂 有效期：2023 年 8 月 7 日至 ...

证券代码：002940 证券简称： 昂利康 | --- | --- | --- | --- | |--------------|---------------------------------|-------------|----------------| | | | | 编号：2023-003 | | 投资者关系活 | | | | | 动类别 | □媒体采访 | □业绩说明会 | | | | □新闻发布会 □路演活动 | | | | | 现场参观 | | | | | □其他（请文字说明其他活动内容） | | | | 参与单位名称 | | | | 及人员姓名 建信基金郑丁源、湘财基金张泉 时间 2023 年 7 月 10 日 15:00 地点 公司二楼小会议室 上市公司接待 董事长助理：孙黎明 人员姓名 证券事务助理：傅书艺 问答与交流： 1、苯磺酸左氨氯地平片集中采购将于七月份开始执行，这 对昂利康有什么样的影响，昂利康对于左益产品未来的策略是 怎么样的？ 答：七月份开始执行集中采购，这对公司左益产品的收入 投资者关系活 和利润将会产生一定影响，尤其是三季度刚开始执行。公司未 动主要内容介 来将继续努力争 ...

Operating Costs and Expenses - Operating costs increased by 74.38% to 230.415 million yuan, mainly due to increased raw material costs[3] - Operating costs increased to 385,934,494.86 yuan, a 31.8% rise from the previous year (292,776,746.73 yuan)[16] - R&D expenses rose by 40.94% to 20.760 million yuan, reflecting increased investment in research and development[3] - R&D expenses grew by 40.9% to 20,760,455.04 yuan compared to 14,730,302.82 yuan in the same period last year[16] Government Subsidies and Other Income - Other income surged by 1028.90% to 19.030 million yuan, primarily due to increased government subsidies[3] - Deferred income rose by 95.46% to 19.025 million yuan, driven by increased government subsidies and the consolidation of Core Biotech[10] Cash Flow and Financing Activities - Investment activities cash flow improved by 79.20%, with net cash outflow decreasing to 41.865 million yuan[7] - Financing activities cash flow turned negative, with a net outflow of 108.128 million yuan, mainly due to loan repayments[7] - Net cash flow from operating activities was 84,860,705.56 yuan, a 5.6% decrease compared to 89,918,248.97 yuan in the same period last year[18] - Cash received from sales of goods and services decreased to RMB 425.59 million from RMB 452.23 million[23] - Cash paid for goods and services increased to RMB 156.36 million from RMB 138.22 million[23] Revenue and Profit - Revenue for the first quarter increased by 25.52% to 424,507,176.32 yuan compared to the same period last year[13] - Revenue for the first quarter of 2023 reached 424,507,176.32 yuan, a 25.5% increase compared to the same period last year (338,209,274.21 yuan)[16] - Net profit attributable to shareholders of the listed company rose by 20.43% to 47,070,207.68 yuan year-on-year[13] - Net profit attributable to the parent company's owners was 47,070,207.68 yuan, up 20.4% year-over-year (39,086,498.56 yuan)[17] - Basic earnings per share (EPS) for the quarter was 0.34 yuan, up from 0.29 yuan in the previous year[17] Assets and Liabilities - Total assets grew by 11.75% to 2,901,032,233.82 yuan compared to the end of the previous year[13] - Total assets increased to 2,843,567,890.12 yuan, up from 2,789,456,789.23 yuan at the beginning of the year[19] - Accounts receivable increased by 63.66% to 32,901,271.84 yuan due to higher bank acceptance bills[14] - Inventory surged by 45.84% to 427,654,334.58 yuan mainly due to the inclusion of Core Biotech in the consolidation[14] - Goodwill skyrocketed by 1374.31% to 323,998,277.56 yuan as a result of recognizing goodwill from Core Biotech's inclusion[14] - Short-term borrowings decreased by 44.74% to 94,046,255.00 yuan due to partial repayment of bank loans[14] - Short-term borrowings decreased to RMB 94.05 million from RMB 170.18 million[21] - Accounts payable jumped by 129.67% to 223,484,300.63 yuan owing to increased raw material payments[14] - Accounts payable increased to RMB 223.48 million from RMB 97.31 million[21] - Contract liabilities decreased by 54.74% to 14.965 million yuan, reflecting reduced prepayments from customers[10] - Contract liabilities decreased to RMB 14.97 million from RMB 33.07 million[21] - Other payables increased by 88.78% to 310.046 million yuan, mainly due to the acquisition of Core Biotech[10] - Deferred tax liabilities surged by 936.49% to 16.631 million yuan, due to the revaluation of Core Biotech[10] - Total current liabilities increased to RMB 859.19 million from RMB 788.59 million[21] - Long-term borrowings increased to RMB 192.05 million from RMB 150.00 million[21] - Total liabilities increased to RMB 1.09 billion from RMB 949.93 million[21] - Total equity increased to RMB 1.81 billion from RMB 1.65 billion[21] Shareholder Information - The company's first employee stock ownership plan holds 2.15% of shares, totaling 2,987,000 shares[15] - The top 10 shareholders hold a significant portion of the company's shares, with the largest being Shengzhou Juntao Investment Co., Ltd. at 49,300,000 shares[15] - The company's largest shareholder, Shengzhou Juntao Investment Co., Ltd., holds a 35.44% stake with 49,300,000 shares[20] - The number of ordinary shareholders at the end of the reporting period was 8,962[20] Other Financial Information - The company acquired two land use rights for a total of 25.84 million yuan, expanding its operational footprint[11] - Cash and cash equivalents at the end of the period stood at 663,576,967.12 yuan, a decrease from 728,897,502.12 yuan at the beginning of the period[18] - The company's Q1 report was not audited[24]

证券代码：002940 证券简称： 昂利康 浙江昂利康制药股份有限公司投资者关系活动记录表 编号：2023-002 投资者关系活动 类别 □特定对象调研 □分析师会议 □媒体采访 业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他（电话会议） 参与单位名称及 人员姓名 参与公司 2022 年年度报告网上业绩说明会的投资者 时间 2023 年 4 月 20 日下午 3:00-5:00 地点 全景•路演天下（http://rs.p5w.net） 上市公司接待人 员姓名 董事长方南平 董事、总经理郑国钢 财务总监毛松英 独立董事赵秀芳 投资者关系活动 主要内容介绍 投资者关系活动主要内容详见附件。 公司接待人员与投资者进行了充分交流与沟通，本次交流严 格按照有关制度规定，没有出现未公开重大信息泄露等情况。 附件清单（如有） 昂利康 2022 年年度报告网上业绩说明会提问答复清单 日期 2023 年 4 月 20 日 1 附件：2022 年年度报告网上业绩说明会提问答复清单 | 序号 | 问题内容 | 回答内容 | | --- | --- | --- | | | 你好，昂利康第四季度研发费用大幅上升，是否今年仍 ...

关于举行 2022 年年度报告网上业绩说明会的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 浙江昂利康制药股份有限公司（以下简称"公司"）2022 年年度报告已于 2023 年 4 月 1 日披露。为便于广大投资者进一步了解公司 2022 年经营情况，公 司定于 2023 年 4 月 20 日（星期四）下午 15:00-17:00 在全景网举行 2022 年年度 报告网上业绩说明会，本次年度报告网上业绩说明会将采用网络远程方式举行， 投资者可登陆全景网"投资者关系互动平台"（https://ir.p5w.net）参与本次年度 业绩说明会或者直接进入公司路演厅（https://ir.p5w.net/c/002940.shtml）参与本 次年度业绩说明会。 出席本次年度网上业绩说明会的人员有：公司董事长方南平先生、总经理郑 国钢先生、财务总监毛松英女士、独立董事赵秀芳女士（如有特殊情况，参与人 员会有调整）。 为做好中小投资者保护工作，公司现就 2022 年度业绩说明会提前向投资者 征集相关问题，广泛听取投资者的意见和建议。投资者可于 2023 年 4 月 ...

Financial Performance - The company's operating revenue for 2022 was ¥1,568,437,219.16, representing a 13.62% increase compared to ¥1,380,377,636.93 in 2021[20]. - The net profit attributable to shareholders for 2022 was ¥127,296,292.01, a 6.22% increase from ¥119,844,202.86 in 2021[20]. - The net profit after deducting non-recurring gains and losses was ¥120,346,889.82, up 11.58% from ¥107,857,508.30 in 2021[20]. - The total assets at the end of 2022 were ¥2,596,083,285.56, a 24.60% increase from ¥2,083,578,310.62 at the end of 2021[20]. - The net assets attributable to shareholders increased by 12.23% to ¥1,502,660,924.92 from ¥1,338,853,095.62 at the end of 2021[20]. - The basic earnings per share for 2022 was ¥0.93, reflecting a 6.90% increase from ¥0.87 in 2021[20]. - The company reported a total revenue of 10,433.70 million in 2022, representing a significant increase compared to the previous year[135]. Risk Management - The company emphasizes the importance of risk awareness regarding industry regulations, rising production costs, and potential talent loss in core technology[4]. - The company has outlined various risks in its management discussion, including the impact of centralized procurement and environmental policies on operations[4]. - The company faces risks from increased production costs due to stricter safety and environmental policies, which may impact overall profitability[105]. - The company is monitoring industry policy changes closely to mitigate risks associated with centralized procurement and price reductions that could affect its product performance[106]. - The company faces risks related to talent shortages and the potential loss of core technical personnel, which could impact operational efficiency[109]. - New drug development is subject to long cycles and various risks, including technical difficulties and market factors, which may delay progress or lead to project failures[110]. Research and Development - The company focuses on R&D as its core development driver, emphasizing the development of clinically valuable products in the competitive generic drug market[34]. - R&D expenses reached CNY 11,262.16 million, a significant increase of 114.30%, accounting for 7.18% of the operating revenue[45]. - The company is advancing multiple important generic drug projects, with several products having received drug registration certificates[62]. - The company aims to enhance its R&D capabilities by increasing investment and optimizing the structure of ongoing projects, with a focus on collaborative R&D and attracting high-end talent[97]. - The company plans to increase R&D investment in the near term, which may temporarily affect operational performance[110]. Corporate Governance - The company emphasizes strict compliance with environmental regulations, ensuring that emissions of waste gas, waste water, and waste residues meet the required standards[107]. - The company strictly adheres to the requirements of the Company Law and other regulations, ensuring a well-structured governance system and protecting the rights of shareholders, particularly minority shareholders[119]. - The company held shareholder meetings in compliance with legal requirements, ensuring equal participation and rights for all shareholders, with complete and transparent meeting records[120]. - The board of directors operates with a clear division of responsibilities, supported by four specialized committees, ensuring professional decision-making[121]. - The company maintains independence from its controlling shareholder in terms of business operations, assets, and financial management, ensuring no conflicts of interest[125]. Environmental Compliance - The company adheres to various environmental standards, including the Class III standard for surface water quality and the Class II standard for air quality[176]. - Wastewater treatment meets the Grade III standard of the "Comprehensive Discharge Standard for Wastewater" (GB8978-1996)[177]. - The company executes strict emission limits for air pollutants according to the "Pharmaceutical Industry Air Pollutants Emission Standards" (DB33/310005-2021)[178]. - The company has implemented noise control measures, adhering to the Class 3 standard for industrial areas, with daytime limits of 65dB and nighttime limits of 55dB[178]. - The company has established wastewater treatment facilities with a design capacity of 1000 tons per day, equipped with an online monitoring system for wastewater flow, pH, COD, and ammonia nitrogen[186]. Employee Engagement and Development - An employee stock ownership plan was launched in April 2022, with the first phase completed in November 2022, aimed at enhancing employee engagement and aligning interests[51]. - The company aims to establish a competitive compensation and benefits system to attract and retain talent, with annual evaluations for new graduates and various performance awards[160]. - The training strategy focuses on internal development supplemented by external recruitment, with programs for leadership, technical skills, and management training[161]. - The company is committed to building a professional lecturer team and internal course development to enhance employee skills and business quality[162]. Strategic Investments - The company is actively managing its subsidiaries and exploring potential mergers and acquisitions to drive growth[4]. - The company has made significant equity investments, including a total investment of ¥200,000,000 in Hunan New Harmony Biopharmaceutical Co., Ltd., acquiring a 10.61% stake[75]. - The company also invested ¥234,800,126.60 in Hunan Kory Biopharmaceutical Co., Ltd., obtaining a 23.48% share[75]. - The company plans to invest 200 million CNY in upgrading its manufacturing facilities to increase production efficiency by 30%[152]. Community Engagement - The company donated 1 million yuan to the Shenzhou Charity Association as part of its corporate social responsibility initiatives[200]. - The company contributed 500,000 yuan to the China Health Promotion Foundation to support public welfare in health promotion[200]. - The company actively participates in social welfare activities, including providing assistance to underprivileged families and donating electronic equipment to local schools[200].

证券代码：002940 证券简称：昂利康 浙江昂利康制药股份有限公司投资者关系活动记录表 | --- | --- | --- | --- | --- | |----------|----------------------------|--------------|------------------|--------| | | | | | | | 投资者关 | □ 特定对象调研 □分析师会议 | | | | | | □ 媒体采访 □业绩说明会 | | | | | 系活动类 | □ 新闻发布会 □路演活动 | | | | | 别 | □ 现场参观 | | | | | | 其他（电话会议） | | | | | 参与单位 | 长江证券 | 方程嫣、刘浩 | 华夏久盈 | 胡攸乔 | | | 招商基金 | 钟赟 | 工银瑞信 | 李善欣 | | 名称及人 | 万家基金 | 王霄音 | 创金合信 | 皮劲松 | | 员姓名 | 神农投资 | 张薇 | 天弘基金 | 郭相博 | | | 国投瑞银 | 周思捷 | 国泰基金 | 林小聪 | | | 百年保险资管 | 陈兴 | 国联安 | 呼荣权 | | | 中信资管 | ...

证券代码：002940 证券简称： 昂利康 浙江昂利康制药股份有限公司投资者关系活动记录表 编号：2020-003 | --- | --- | --- | |--------------|----------------------------|-----------------------------------------------------------| | | | | | 投资者关系活 | | 特定对象调研 □分析师会议 | | | □ | 媒体采访 □业绩说明会 | | 动类别 | □ | 新闻发布会 □路演活动 | | | □ 现场参观 | | | | | □其他（请文字说明其他活动内容） | | 参与单位名称 | 国海证券周超泽、徐晓欣 | | | 及人员姓名 | | | | 时间 | 2020 年 5 月 12 | 日下午 2:00 | | 地点 | 公司董事会办公室 | | | 上市公司接待 | | | | 人员姓名 | 副总经理、董事会秘书孙黎明 | | | 投资者关系活 | 一、介绍公司基本情况 | | | | | 公司主要从事的业务为医药生产制造业务，主要包括化学 | | 动主要内 ...